[MO5] Mini-Oral Session 5　肝胆膵2（HCC・膵がん）
【E】

[MO5-3] Efficacy and Patient-report outcomes of Atezolizumab/Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand

^○Chanchai Charonpongsuntorn¹, Suebpong Tanasanvimon², Krittiya Korphaisarn³, Songwit Payapwattanawong⁴, Teerada Siripoon⁵, Jitlada Juengsamarn⁶, Ekkamol Phaibulvatanapong⁷, Jarin Chindaprasirt⁸, Naiyarat Prasongsook⁹, Kittipong Udomdamrongkul¹⁰, Nussara Pakvisal², Nuttapong Ngamphaiboon⁵, Ekaphop Sirachainan⁵ (1.Medical Oncology Unit, Department of Internal Medicine, Srinakharinwirot University, 2.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 3.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, 4.Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, 5.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital Mahidol University, 6.Oncology Unit, Department of Medicine, Sunphasitthiprasong Hospital, 7.Oncology Unit, Department of Medicine, Samutprakarn Hospital, 8.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Kaon Kaen University, 9.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Phramongkutklao University, 10.Oncology Unit, Department of Medicine, Taksin Hospital)